J&J’s COVID-19 shot scores safety backing from CDC experts but booster need left for FDAnews2021-07-22T20:32:45+00:00July 22nd, 2021|Fierce Pharma|
Once conditional, Merck’s Keytruda, Eisai’s Lenvima win full approval for endometrial cancernews2021-07-22T16:10:03+00:00July 22nd, 2021|Fierce Pharma|
Biogen execs blame critics, the media for spurring ‘misinformation’ as Aduhelm launch lags expectationsnews2021-07-22T15:25:00+00:00July 22nd, 2021|Fierce Pharma|
Roche pharma chief pegs $2B boost to Polivy’s potential lymphoma expansion as drugmaker weathers biosimilarsnews2021-07-22T14:51:24+00:00July 22nd, 2021|Fierce Pharma|
A $200M injection from the U.S. will allow Aspen to produce more Johnson & Johnson COVID-19 vaccines for Africanews2021-07-22T14:27:53+00:00July 22nd, 2021|Fierce Pharma|
Trade group trio raises drug shortage alarm as FDA ups its carcinogen testing effortsnews2021-07-22T12:12:06+00:00July 22nd, 2021|Fierce Pharma|
Pfizer’s immunology ambitions delayed—again—as JAK drugs fall victim to FDA’s protracted safety reviewnews2021-07-22T09:43:51+00:00July 22nd, 2021|Fierce Pharma|
Done deal: Johnson & Johnson and 3 distributors agree to historic $26 billion opioid settlementnews2021-07-21T20:38:12+00:00July 21st, 2021|Fierce Pharma|
Johnson & Johnson eyes $2.5B in COVID vaccine sales as key immunology, oncology meds trounce expectationsnews2021-07-21T15:20:10+00:00July 21st, 2021|Fierce Pharma|
AstraZeneca closes mega $39B Alexion buyout despite antitrust fears, making a splash in rare diseasesnews2021-07-21T15:05:53+00:00July 21st, 2021|Fierce Pharma|
